A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
The Perils and Promise of Partnerships Between Biopharma and Data Companies
The Perils and Promise of Partnerships Between Biopharma and Data Companies
Top Pharma News of the Week
Top Pharma News of the Week
Pfizer Snags FDA Approval for New Lung Cancer Drug Vizimpro
Pfizer Snags FDA Approval for New Lung Cancer Drug Vizimpro
Top News from the IASLC 19th World Conference on Lung Cancer 2018
Top News from the IASLC 19th World Conference on Lung Cancer 2018
Tecentriq sets the bar in small-cell lung cancer
Tecentriq sets the bar in small-cell lung cancer
Takeda’s Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
Takeda’s Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
Top Pharma News of the Week
Top Pharma News of the Week
AstraZeneca’s Imfinzi Cuts Lung Cancer Death by a Third
AstraZeneca’s Imfinzi Cuts Lung Cancer Death by a Third
Debate Over the Orphan Drug Act Heats Up
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and … Continue Reading Debate Over the Orphan Drug Act Heats Up
Top Pharma News of the Week
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases August 14, 2018 Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement … Continue Reading Top Pharma News of the Week
Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program
The U.S. Food and Drug Administration (FDA) granted Merck & Co.’s Keytruda another approval, this one in combination with Alimta (pemetrexed) and platinum chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), with … Continue Reading Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program
Top Pharma News of the Week
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On … Continue Reading AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report
Takeda’s Alunbrig Shows Superiority Over Pfizer’s Xalkori in Some Lung Cancer Patients
Takeda Pharmaceutical‘s Alunbrig (brigatinib) hit its Phase III primary endpoints of statistically significant improvement in progression-free survival compared to crizotinib (Pfizer’s Xalkori) in a subset of lung cancer patients following the first pre-specified … Continue Reading Takeda’s Alunbrig Shows Superiority Over Pfizer’s Xalkori in Some Lung Cancer Patients
Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver … Continue Reading Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough
